YangShiMD

Pathology • Bronx, NY

Hematopathology, Anatomic Pathology, Clinical Pathology

Pathology Resident, Duke University Medical Center

Join to view full profile

Dr. Shi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shi's full profile

Already have an account?

Office
111 E 210th St
Bronx, NY 10467
Phone+1 718-920-6006

Education & Training

Duke University HospitalResidency, Pathology-Anatomic and Clinical, 2012 - 2014
University of California (Irvine)Residency, Pathology-Anatomic and Clinical, 2010 - 2014
China Medical University ShenyangClass of 1999, MD

Certifications & Licensure

NY State Medical License 2015 - 2026
CA State Medical License 2013 - 2025
NC State Medical License 2012 - 2014
American Board of Pathology Pathology - Anatomic/Pathology - Clinical
American Board of Pathology Pathology - Hematology

Publications & Presentations

PubMed

50 citations
Selective downregulation of mitochondrial electron transport chain activity and increased oxidative stress in human atrial fibrillation
Larisa Emelyanova, Zain Ashary, Milanka Cosic, Ulugbek Negmadjanov, Gracious R Ross
American Journal of Physiology. Heart and Circulatory Physiology. 2016-07-01
383 citations
The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3
Shaila Rahman, Mathew E. Sowa, Matthias Ottinger, Jennifer A. Smith, Yang Shi
Molecular and Cellular Biology. 2011-07-01
367 citations
RAG2 PHD finger couples histone H3 lysine 4 trimethylation with V(D)J recombination
Adam G. W. Matthews, Alex J. Kuo, Santiago Ramón-Maiques, Sunmi Han, Karen S. Champagne
Nature. 2007-12-13

Press Mentions

Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients with Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate EndpointNovember 11th, 2021
Flock of New Folds Fills in Tauopathy Family TreeOctober 5th, 2021
Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial CancerAugust 26th, 2021
Join now to see all